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TABLE 11. S MMARY OF CASES TREATED WITH NATUL
demonstrable pathological lymph nodes or a measurable
reduction in size of an enlarged liver or spleen, lasting for
1 month or longer. on-specific and subjective improve-
ment. such as a fall in sedimentation rate, relief from
itchi~g, etc., although valuable as complementary signs of
remission, alone were not considered an indication of
successful treatment.
The response symbols used in individual cases in Table
IH are those uggested by Karnofsky; viz.:
Calegory 0: 0 clinically useful effect on course of disease.
0-0: Disease progresses; no subjective benefit.
0- A*: Disease progresses; subjective benefit without
favourable objective changes.
0- B*: Favourable objective changes without subjec-
tive benefit.
o -C: Subjective benefit and favourable objective
changes in measurable criteria, but of less than
I month's duration; then the disease pro-
gresses.
Category I: Clinical benefit with favourable objective
changes in all measurable criteria of disease.
1- A*: Distinct subjective benefit with favourable ob-
jective changes in all measurable criteria for I
month or more.
1- B* : Objective regression of all palpable or measur-
able neoplastic disease for 1 month or more in
a relatively asymptomatic patient who is able
to carry on his usual activities without undue
difficulty.
1- C Complete relief of symptoms, if any, and re-
gression of all manifestations resulting from
the active disease for 1 year or more.
Category Il: Interruption or slowing in progression of
disease without definite evidence of subjective
or objective improvement.
*Superscnpt is lime in months of duration of response.
28 19
Procarbazine ( atulan; Ro 4-6467; N-isopropyl-a-[2-
methyl-hydrazino]-p-toluamide hydrochloride) is a syn-
thetic compound which belongs to a new class of anti-
tumour agent, the methyl hydrazine derivatives. Bollag
and Grunberg' reported on the inhibitory effects of these
agents on various transplantable rodent tumours. Clinical
studies have been under way since 1962. It has generally
been concluded that these compounds are of 'consider-
able' value in the treatment of Hodgkin's disease.'" Bene-
ficial effects have also been noted in other lymphomas:-'
malignant melanoma' and oat-cell carcinoma of the lung."
The mode of action of this group of compounds has not
yet been completely elucidated. The effect has been com-
pared to the indirect effect of ionizing radiation. In cytolo-
gical studies I-methyl-2-benzyl hydrazine has been shown
to inhibit mitosis by prolonging the interphase of cell
division.' This evidently results from a disintegratory
effect (depolymerization) of the methyl hydrazine on des-
oxyribonucleic acid (D A), the main constituent of the
chromosomes.s
MATERIALS A!''D METHODS
Twenty-eight patients with malignant lymphoma were selected
for therapy with atulan. The diagnoses were as follows:
Hodgkin's disease in 21; reticulum-cell sarcoma in 5: lympho-
sarcoma in 1; and mycosis fungoides in 1. All patients had
features of systemic disease and chemotherapy was a clear
indication. Only 6 cases had not received previous treatment:
for the rest, all had been treated by radiotherapy and/or at
least 1 cytotoxic agent; 5 cases had been resistant to all avail-
able methods of treatment, i.e. radiotherapy, one or more of
the alkylating agents and vinblastine sulphate.
Histological confirmation of disease was obtained in every
case before treatment was started.
The patients' ages varied between 12 and 70 years: the
majority being males between the ages of 21 and 50 (Table I).
TABLE J. AGE AND SEX DISTR!BUTION II': 28 CASES OF LYMPHOMA
Sex Age
Total Orer 50
M F 0-20 21-50
















The drug (supplied in capsules containing 50 mg. and
ampoules containing 250 mg.) was administered intravenously
in isotonic saline (I case only) or orally (27 cases). In most
patients a dose of 300 mg. per day was aimed at and, depend-
ing on the white cell count, maintenance dosage was instituted
at 50 - 150 mg. / day. Total dosage varied between 1·25 and
60-4 G. In the initial stages blood counts were obtained twice
a week. but after stabilization these were done as infrequently
as once every 4 - 6 weeks. Treatment on an outpatient basis
presented no special problems.
RESULTS OF TREATMENT
Of the 28 patients treated, 19 showed 'worth-while' clinical
improvement while receiving the drug. Treatment was
considered successful only in the presence of measurable
objective improvement, i.e. regression of 50% or more of
"'Member and tHead of the Cancer Chemotherapy Section. supported by a
grant from the lational Cancer Association of South Africa.
Hodgkin's disease. Of 21 cases, 16 improved with regres-
sion of enlarged lymph nodes, reduction in the size of an
enlarged liver or spleen, disappearance of fever or itching
and improvement of general condition as evidenced by
weight gain, improvement of appetite, etc. In one patient
there was marked improvement of bilateral pleural effu-
sions within 3 weeks of commencing treatment. This
patient incidentally had previously responded poorly to
cyclophosphamide.
Reticulum·cell sarcoma. There was definite improve-
ment in 2 patients with diffuse skin lesions, although in
one of these remission lasted for only about 3 months.
The other was still in good remission, at the time of
writing, 8 months after treatment was started.
Lymphosarcoma. Jn one patient treated, no objective
response was seen.
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TABLE Ill. SUMMARY OF PATIENTS TREATED WITH ATULAN
10 Desember 1966
Patient Diarwosis fllld Dominant clinical
------ duration of disease features



































































































































oedema of penis and
scrotum due to lvm~
phatic obstructio-n
Progressive anaemia






















































































































































































Complete resolution of all
lesions. Drug temporarily
stooped because of agranulocy-
tosis. Still in remission after 18
months on maintenance treat.
ment
Marked imorovement of dysp-
noea as effusions cleared. Other
lesions re~ressed oartially. Then
developed paraplegia and died
3 months later
o improvement noted. Vin-
blastine sulphate given subse·
quently, like".. ise had no effect
Very good resoonse. Still in
remission on maintenance treat·
ment
Subjective imorovement only.
Responded well to subsequent
radiotherapy
Complete disappearance of lym-
phadenopathy and marked
shrinkage of spleen. Still on
maintenance treatment
Complete remission. Still on
maintenance treatment
Complete remission. Treatment
temporarily stopped because of
leucopenia
St~ady rise in haemoglobin.
Fever subsided. Jaundice cleared
as hepatomegaly regressed.
Treatment temporarily stopped
because of leucopenia. PS
improved from C to A. Still in
remission on maintenance treat-
ment
All lesions m'lrkedly improved
Marked improvement of lesions
on feet. Remission lasted for 3
months
Some improvement in backache
occurred but measurable lesion
did not regress. Responded
favourably to subsequent ad-
ministration of vinblastine sul~
phate
All lesions regressed but neuro-
logical side-effects (disorienta-
tion and drowsiness) pr'~c1uded
further treatment
Good response. Jaundice dis·
appeared. Steady rise in haemo-
globin. No palpable lesions in
abdomen. Still in remission
Measurable lesions improved,
but this lasted for only 4 months.
Thereafter steady downhill
course and patient died 31 days
after treatment W3S stopped
Lung infiltration cleared and
performance status improved to
A. Treatment stopped because
of side-effects (leucopenia. nau-
sea and vomiting)
No effect noted. Died 22 days
after start of treatment
Lung infiltration cleared. Per-
formance status improved to A.
Remission lasted for 3 months
only
Backache much better. Regres-
sion of all lesions
Complained of severe nausea
and vomiting. Treatment did not




Treatm~nt stopped because of
side-effecls. Severe leucopenia
occurred as well as thrombocy-
topenia and neurological symp-
toms (disorientation + +)
Lesions regressed, but treatment
had to be stopped because of
leucopenia and drowsiness. Then
hepatomegaly and lung infiltra-
tion occurred
ImIJrovement of lymphadeno-
pathy noted but disease relapsed
before white cells recovered
com:>letely
Treatm:nt stopped because of
severe drowsiness and dis-
orientation. 0 improvement
noted
Complete remission which tasted
for 15 months before disease
relapsed
Disappearance of skin lesions
for 3 months before exacerba-
tion of disease occurred
Died suddenly 18 days after
start of treatment. No effect
noted
~1arked improvement of all
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TABLE Ill. (CONr'D.)
Dosage
Patient Dia~1l0~iis and Dominant clinical LOk:esl Prel'iou\'" Responset
duration of disease features ps' Period Total WBC treatment category
No. Sex Age (days) (mg.) count
21 F 65 Hodgkin's Skin infiltrati'Jn face C 38 10.950 800 Radiotherapy 0-0
disease and scalp. LVffioha-
:,::6 mths. denopathy. Infiltra-
tion lungs
22 M ~7 Hodgkin's Liver infiltration. A 9 1.250 1,600 Radiotherapy O-C
disease Marked splenomegaly.
8 mths. Lymphadenopathy
23 M 55 Hodgkin's Lymphadenopathy B 34 10,200 3,200 Cyclophosphamide. I_A'
disease (cervical and medias- Vinblastine sul-
10 mths. tinal). Anaemia phate. Radiotherapy
24 M 46 Hodgkin's Jaundice. Abdominal D 15 5.375 7.800 Cyclophosphamide. 0-0
disease distension. Hepato- (IV) Vinblastine sul-








ses. Large mass of






*PS: Performance status defined by the following symbols: A = normal activity; B = unable to work. but living at home and caring for mOSt personal neejs:
C = Unable to care for personal needs; 0 = very iJI. bedridden or paraplegic patient.
tResponse category as suggested by Kamofsky.9 See text.
TABLE V. SIDE-EFFECTS I ' 28 PAT/ENrS TREATED WITH NATULAN
Toxidty (Table V)
TABLE IV. EFFECT OF PREVIO S TREATMENT (PT) ON RESPONSE TO
METHYL HYDRAZINE IN 25 CASES OF LYMPHOMA
the form of radiotherapy and / or at least one cytotoxic
agent; 5 of these were resistant to both alkylating agents
and the vinca alkaloids.
1. Gastro-intestinal. ausea and vomltmg are the most
frequent complications of treatment with this drug and
occur in the majority of patients if the initial dosage is
stepped up too rapidly. These side-effects can however be
avoided almost completely by a slow increase of the daily
dose, starting with 50 mg. a day and increasing by 50 mg.
increments up to 300 mg./day. A dose of more than 300
mg. per day is hardly ever necessary.
In this series severe nausea and vomiting occurred in 5
cases, but in only 2 of these was it necessary to stop
administration of the drug.
Judicious administration of anti-emetics, i.e. prochlor-
perazine, 1 - 2 mg./day, may be of considerable help in
controlling nausea.
2. H aemalOlogical. Bone-marrow depression is a fre-
quent complication of the administration of methyl hydra-
zine derivatives. In this series leucopenia (WBC less than
4.000) was observed in 19 cases. The lowest white cell
count encountered was 800/ cU.mm.; this occurred after
a total dose of only 10·9 G. Frequent mention is made of
the fact that leucopenia commonly occurs after the ad-
ministration of approximately 6 - 8 G. unless damage ha
already been caused by previous X-ray treatment or
administration of other cytostatics. In this respect it i of
note that one patient in this series showed no signs of
bone-marrow depression whatsoever, even after the ad-
ministration of 53·25 G of Natulan.
There did not seem to be a selective effect on poly-
morphs or other cells of the white cell series.
The red cell count and haemoglobin were on the whole
unaffected by treatment.
Thrombocytopenia occurred in 2 cases, but this was not
accompanied by purpura or haemorrhagic tendencies and














It is interesting to note the response with regard to
previous treatment (Table IV). Of the 19 cases that im-
proved no less than 14 had received previous treatment in
Mycosis fungoides. The only patient treated showed
well-marked improvement, although this lasted for only
3 months before resistance to cytostatics developed.
Cases improved Failures
Neoplasms
Total PT Total PT
Hodgkin's disease 16 11 5 4
Reticulum-cell sarcoma .. 2 2 1 I
Lymphosarcoma 0 0 I I
Mycosis fungoides I I 0 0
Total 19 14 7 6
I. Severe nausea and vomiting
2. Leucopenia (WBC lower than 4,OOO/cu.mm.)
3. Thrombocytopenia






10. Teurological symptoms (euphoria, psychosis,
delirium, drowsiness, disorientation, coma) ......
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As this drug is a hydrazine derivative, mention is made
of haemolysis occurring during treatment with Natulan.'
We have not observed overt haemolysis, although regular
reticulocyte counts and other tests for occult haemolysis
were not performed as a routine.
3. ellrological symptoms were observed in 4 patients,
in 2 of these after the concurrent administration of pheno-
thiazines. One patient, an elderly woman, became ex-
tremely restless and slightly confused, but this disappeared
after withdrawal of phenothiazines and other sedatives.
The other patient became very drowsy and would certainly
have gone into a coma if we had not been aware of this
disturbing side-effect.
4. Other side-effects. A 'flush syndrome' occurred in 2
patients after the intake oC alcohol. One patient com-
plained of a very dry mouth, but this improved after a
reduction in the dose of Natulan.
Skin rashes, alopecia and hyperglycaemia were not en-
countered in any of the cases treated in this series.
DISCUSSION
Procarbazine has a very definite place in the treatment of
Hodgkin's disease. It has already been mentioned by
others'" that the frequency of obtaining a remission with
this drug is approxima'ely the same as for vinblastine and
the alkylating agents in common use. This applies also for
the quality and duration of remissions and, if any, rem:s-
sions obtained with procarbazine last longer than those
seen with vinblastine.'
In view of these findings it seems quite logical that 'the
order in which these agents are used in the treatment of
Hodgkin's disease is likely to be governed by considera-
tions such as ease of administration and freedom from
side-effects'.' Oral administration is a distinct advantage
over vinblastine, whereas alopecia, so frequently observed
with cyclophosphamide (the alkylating agent mostly em-
ployed by us), has not yet been described in cases treated
with procarbazine. Mathe et al.' also mention the fact
that treatment with the drug is easier than with another
effective alkylating agent-trisethylene melamine. Apart
from troublesome nausea in some cases, patients have
generally tolerated the drug very well.
We have been particularly impressed by the frequency
of remissions in cases resistant to other cytostatics-not-
ably the absence of 'cross-resistance' with the alkylating
agents and vinblastine.
In the management of localized Hodgkin's disease radio-
therapy remains the treatment of choice and neither pro-
carbazine nor any other chemotherapeutic agent should
replace it in these cases. Other diseases of the lymphoma-
group respond more variably but even in these cases
gratifying results may be obtained.
SUMMARY
Procarbazine (Natulan, Ro 4-6467), a new methyl hydrazine
derivative, has been used in the treatment of advanced malig-
nant lymphomas, with particularly good effect in cases of
Hodgkin's disease. 'Worth-while' clinical improvement was
noted in 16 of 21 cases with Hodgkin's disease, 2 of 5 patients
with reticulum-cell s:.-rcoma and in I case of mycosis fun-
goides.
An impressive feature h<:.s been the frequency of remissions
in cases previously treated and resistant to radiotherapy, the
alkylating agents and/or vinblastine.
It is concluded that Natulan should be considered in the
primary treatment of generalized Hodgkin's disease, and that
it is definitely indicated in cases resistant to other available
agents, including radiotherapy.
The atulan (Ro 4-6467) used in this study was kindly
supplied by Roche Products Ltd., Johannesburg.
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VENOUS LIGATION FOR SEPTIC PULMONARY EMBOLI FOLLOWING SUPPURATIVE
PELVIC THROMBOPHLEBITIS
H. R. KLEIN, M.B., B.CH., M.R.C.O.G., M.R.C.P. (LoND. A.!'o'D EDIN.), Department of Obstetrics and Gynaecology,
University of the Witwatersrand, }ohannefbllrg, A D FAY SEGAL, M.B., B.CH., M.D. (RAND), Department of Medicine,
Baragwanath Hospital, Johannesburg
Ligation of the inferior vena cava, for pyaemic metastatic
abscesses due to septic emboli from suppurative pelvic
thrombophlebitis, is not a new procedure. Despite the con-
trol and eradication of pyaemia in obstetrical and gynaeco-
logical practice, there exists a small number of cases where
ligation of the venous drainage from the pelvis may be a
life-saving measure.'
In cases of puerperal pyaemia, Trendelenburg' and
Miller' demonstrated the presence of palpable thrombosed
veins at operation. They ligated these individual veins
proximal to the thrombus. Uninvolved branches of the
inferior vena cava and ovarian veins were not ligated. As
their mortality rates were only slightly better than those
following expectant therapy, this method fell into dis-
repute.
However, it was Coli ins et al.' who showed that surgical
ligation could be highly successful in cases of pyaemia,
even though medical treatment had failed. This they
achieved, by completely interrupting the venous return
from the uterus and ovaries by ligating the inferior vena
cava and the ovarian vessels, irrespective of the site of the
venous thrombophlebitis.
Five cases of septic pulmonary emboli following suppu-
rative pelvic thrombosis are presented. Conservative treat-
ment had failed, and ligation of the inferior vena cava
was considerably beneficial and a life-saving procedure.
